BeiGene, Ltd. Price & Performance (ONC)

Zymeworks has fast-tracked its investigational new drug (IND) application for ZW251 to mid-2025, reflecting strategic resource allocation. The company also reported $324.2 million in cash reserves, ensuring financial stability into the second half of 2027. Recent FDA approval of Ziihera® for HER2-positive biliary tract cancer further highlights its advancing oncology portfolio.1

Bernstein increased BeiGene's stock price target to $259, citing strong prospects for its drug sonrotoclax and early-stage candidate BGB-16673. The firm revised peak sales projections for sonrotoclax to $1.9 billion, doubling earlier estimates, and highlighted BeiGene's improved financial discipline and operational efficiency.2

BeiGene insider Xiaodong Wang sold 41,760 shares, valued at approximately $10.9 million, at an average price of $261.28 per share. This follows a prior sale of 8,146 shares earlier in March. Despite the insider activity, BeiGene's stock remains robust, trading near its 52-week high of $287.88.3